Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # http://www.gsk.com/media/press-releases/2012/FDA-approves-new-indication-for-PROMACTA-eltrombopag.html # Zekry A, Freiman J: Eltrombopag: Is this "24 karat gold platelet" treatment for thrombocytopenia in cirrhosis associated with hepatitis C? Hepatology. 2008 Apr;47(4):1418-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18366111 # Mondelli MU: Eltrombopag: An effective remedy for thrombocytopaenia? J Hepatol. 2008 Jun;48(6):1030-2. Epub 2008 Mar 31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18433923 # Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A: Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/ 23492914 # Kiang TK, Ensom MH, Chang TK: UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132. Epub 2005 Jan 12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15781124 # Deng Y, Madatian A, Wire MB, Bowen C, Park JW, Williams D, Peng B, Schubert E, Gorycki F, Levy M, Gorycki PD: Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos. 2011 Sep;39(9):1734-46. doi: 10.1124/dmd.111.040170. Epub 2011 Jun 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21646437 # Kuter DJ: The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013 Jul;98(1):10-23. doi: 10.1007/s12185-013-1382-0. Epub 2013 Jul 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23821332 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - About 21-32 hours in healthy patients. About 26-35 hours in patients with idiopathic thrombocytopenic purpura. (en)
|
http://linked.open...ugbank/indication
| - Thrombopoietin receptor agonists are pharmaceutical agents that stimulate platelet production in the bone marrow. In this, they differ from the previously discussed agents that act by attempting to curtail platelet destruction. (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor. Eltrombopag is a stimulator of STAT and JAK phosphorylation. Unlike recombinant TPO or romiplostim, Eltrombopag does not activate the AKT pathway in any way. It should be noted that when given to patients with aplastic anemia, other lineages besides platelet count were increased, suggesting that either eltrombopag enhanced the effect of TPO in vivo; or there is a yet uncovered mechanism of action at work. (en)
|
http://linked.open...y/drugbank/patent
| |
http://linked.open...outeOfElimination
| - Eltrombopag is eliminated primarily via the feces (59%), along with 31% being renally excreted. (en)
|
http://linked.open.../drugbank/synonym
| - Eltrombopag (en)
- Eltrombopagum (en)
- Promacta (en)
|
http://linked.open...drugbank/toxicity
| - Eltrombopag may cause hepatotoxicity, especially if administered in combination with interferon and ribavirin in patients with chronic hepatitis C (may increase the risk of hepatic decompensation). (en)
|
http://linked.open...umeOfDistribution
| - Based on a radiolabel study, the concentration of eltrombopag in blood cells is approximately 50% to 79% of plasma concentrations. (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...nk/proteinBinding
| - Eltrombopag is highly protein bound (>99%). (en)
|
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Peak absorption of Eltrombopag occurs around 2-6 hours following oral administration, and the total oral absorption of drug-related material following a 75 mg dose was estimated to be at least 52%. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |